In:
Antiviral Therapy, SAGE Publications, Vol. 10, No. 5 ( 2005-07), p. 681-690
Abstract:
The aetiological agent for severe acute respiratory syndrome (SARS) has been determined to be a new type of coronavirus (SARS-CoV) that infects a wide range of mammalian hosts. Up to now, there have been no specific drugs to protect against SARS-CoV infection, thus developing effective strategies against this newly emerged viral infection warrants urgent efforts. Adoptive immune therapy with pathogen-specific heterologous immunoglobulin has been successfully used to control the dissemination of many viral infections. To investigate whether a neutralizing antibody against SARS-CoV raised in an artiodactylous host can have a protective role on primate cells, we prepared serum IgGs and their pepsin-digested F(ab’) 2 fragments from horses inoculated with purified SARS-CoV (BJ-01 strain). The protective effect of the F(ab’) 2 fragments against SARS-CoV infection was determined in cultured Vero E6 cells by cytopathic effect (CPE), MTT and plaque-forming assays and in a Balb/c mouse model by CPE and quantitative RT-PCR. The results showed the neutralization titres of F(ab’) 2 from three horses all reached at least 1:1600, and 50 μg of the F(ab’) 2 fragments could completely neutralize 1x10 4 TCID 50 SARS-CoV in vivo. Additionally, we observed that F(ab’) 2 against BJ-01 strain could also protect cells from infection by the variant GZ-01 strain in vitro and in vivo. Our work has provided experimental support for testing the protective equine immunoglobulin in future large primate or human trials.
Type of Medium:
Online Resource
ISSN:
1359-6535
,
2040-2058
DOI:
10.1177/135965350501000504
Language:
English
Publisher:
SAGE Publications
Publication Date:
2005
detail.hit.zdb_id:
2118396-X
SSG:
15,3
